Simcere Zaiming Pharmaceutical Co. Ltd. has announced clinical trial approvals in China and the U.S. for its CDH6-targeting antibody-drug conjugate (ADC), SIM-0505, for advanced solid tumors. A global clinical study will evaluate SIM-0505 in various malignant tumors, including ovarian cancer and renal cancer.
Simcere Zaiming Pharmaceutical Co. Ltd. has synthesized antibody-drug conjugates (ADC) comprising humanized monoclonal antibodies targeting CDH6 covalently linked to a camptothecin analogue through a linker.
Oncusp Therapeutics Inc. has received IND clearance from the FDA to begin clinical trials with CUSP-06, a cadherin-6 (CDH6)-targeting antibody-drug conjugate designed for the treatment of multiple solid tumors. CDH6 is overexpressed in cancers including ovarian, renal, uterine, thyroid, lung, and cholangiocarcinoma. A phase I trial will pave the way for expansion in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
Cadherin 6 (CDH6) is a transmembrane protein with high expression during embryonic kidney development, with very limited expression in adult tissues but overexpressed in several malignancies such as ovarian or renal cancer, and it is tied disease progression and poor prognosis. This pattern of expression makes it an attractive target for antibody-drug conjugate (ADC) development.
